152 related articles for article (PubMed ID: 3747638)
1. Development of new anti-cancer drugs.
Pinedo HM
Med Oncol Tumor Pharmacother; 1986; 3(2):63-9. PubMed ID: 3747638
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.
Staquet MJ; Byar DP; Green SB; Rozencweig M
Cancer Treat Rep; 1983 Sep; 67(9):753-65. PubMed ID: 6883351
[TBL] [Abstract][Full Text] [Related]
3. A prospective screening program: current screening and its status.
Goldin A; Venditti JM
Recent Results Cancer Res; 1981; 76():176-91. PubMed ID: 7232850
[No Abstract] [Full Text] [Related]
4. The new NCI screen and its implications for clinical evaluation.
Goldin A; Venditti JM
Recent Results Cancer Res; 1980; 70():5-20. PubMed ID: 7355249
[No Abstract] [Full Text] [Related]
5. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute.
Goldin A; Venditti JM; Macdonald JS; Muggia FM; Henney JE; Devita VT
Eur J Cancer (1965); 1981 Feb; 17(2):129-42. PubMed ID: 6894902
[No Abstract] [Full Text] [Related]
6. The preclinical new drug research program of the National Cancer Institute.
Driscoll JS
Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
[TBL] [Abstract][Full Text] [Related]
7. Future clinical perspectives. A concluding discussion.
Eckhardt S
Antibiot Chemother (1971); 1980; 28():147-52. PubMed ID: 7416727
[TBL] [Abstract][Full Text] [Related]
8. Human tumor testsystems: a new screening approach.
Kraemer HP; Sedlacek HH
Behring Inst Mitt; 1986 Jun; (80):103-12. PubMed ID: 3753367
[TBL] [Abstract][Full Text] [Related]
9. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
Venditti JM
Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
[No Abstract] [Full Text] [Related]
10. A modified screening system to select new cytostatic drugs.
Kraemer HP; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):301-28. PubMed ID: 6383326
[No Abstract] [Full Text] [Related]
11. Screening at the National Cancer Institute.
Goldin A; Venditti JM; Carter SK
Natl Cancer Inst Monogr; 1977 Mar; (45):37-48. PubMed ID: 337155
[No Abstract] [Full Text] [Related]
12. Preclinical phase II studies in human tumor lines: a European multicenter study.
Boven E; Winograd B; Fodstad O; Lobbezoo MW; Pinedo HM
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):567-73. PubMed ID: 3383962
[TBL] [Abstract][Full Text] [Related]
13. Nude mouse models as predictors of chemotherapy in man: thymidine and pyrimidines.
Goldin A; Wolpert-Defilippes MK
Bull Cancer; 1979; 66(1):61-6. PubMed ID: 420948
[TBL] [Abstract][Full Text] [Related]
14. Utilization of nude mice in research on human cancer--screening system of anticancer agents using human tumor xenografts in nude mice.
Ueyama Y
Prog Clin Biol Res; 1987; 229():287-310. PubMed ID: 3601990
[TBL] [Abstract][Full Text] [Related]
15. [New models of experimental chemotherapy of tumors].
Treshchalina EM; Andronova NV; Kobliakov VA; Raĭkhlin NT
Vopr Onkol; 2001; 47(6):701-5. PubMed ID: 11826492
[TBL] [Abstract][Full Text] [Related]
16. The discovery and development of new antileukemic drugs.
Grever M; Malspeis L
Hematol Oncol Clin North Am; 1993 Feb; 7(1):233-54. PubMed ID: 8449860
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
18. [New approaches in experimental cancerology: in search of therapeutic models].
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Pierré A; Hickman J
Bull Cancer; 2001 Jan; 88(1):75-84. PubMed ID: 11182656
[No Abstract] [Full Text] [Related]
19. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review).
Winograd B; Boven E; Lobbezoo MW; Pinedo HM
In Vivo; 1987; 1(1):1-13. PubMed ID: 2979758
[TBL] [Abstract][Full Text] [Related]
20. Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?
Damia G; D'Incalci M
Eur J Cancer; 2009 Nov; 45(16):2768-81. PubMed ID: 19762228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
